Of the 354 records reviewed, 125 patients (35.3%) were documented as receiving a ChEI between September 1996 and July 2002, and their data were included in the analysis. Patient characteristics ...

Guidelines are urgently needed on the judicious use of cholinergic drugs. Cholinesterase inhibitors remain pivotal to the treatment of Alzheimer disease (AD), but no specific guidelines are ...

Although numerous studies have demonstrated the potential benefits of ChEIs, the use of these drugs in clinical practice has not been well described and may differ from that in clinical trials. In ...

Two types of drugs have been approved by the FDA to treat Alzheimer's disease: Cholinesterase inhibitors and memantine. Both change the way the brain interacts with important chemicals that are ...

It sees advancements with new drug classes like cholinesterase inhibitors. The global ... focusing on understanding the underlying mechanisms of neuronal damage and cognitive impairment, Technavio ...